دورية أكاديمية
Current and emerging therapies for localized high-risk prostate cancer
| العنوان: | Current and emerging therapies for localized high-risk prostate cancer |
|---|---|
| المؤلفون: | Moris, Lisa, Devos, Gaëtan, Milonas, Daimantas, Albersen, Maarten, Berghen, Charlien, De Meerleer, Gert, Wout, Devlies, Everaerts, Wouter, Gevaert, Thomas, Van Poppel, Hendrik, Claessens, Frank, Joniau, Steven |
| المصدر: | Expert review of anticancer therapy, Oxford : Taylor & Francis, 2021, vol. 21, no. 3, p. 267-282 ; ISSN 1473-7140 ; eISSN 1744-8328 |
| سنة النشر: | 2021 |
| المجموعة: | LSRC VL (Lithuanian Social Research Centre Virtual Library) / LSTC VB (Lietuvos socialinių tyrimų centras virtualią biblioteką) |
| مصطلحات موضوعية: | Androgen receptor signaling inhibitors, Radiation therapy, Radical prostatectomy, high-risk prostate cancer, multimodal treatment, review |
| الوصف: | Introduction: Despite progress in the field of high-risk localized prostate cancer (HRPCa) treatments, high-risk patients treated with curative intent are at increased risk of experiencing PSA failure, metastatic progression and cancer-related death. The optimal treatment strategy for these patients remains a topic of debate. This review provides an overview of the current and investigational therapeutic options for HRPCa treatment. Areas covered: A PubMed search was performed for papers on the current evidence and perspectives on the multimodality treatment of HRPCa. We focus on both primary local treatment as well as systemic treatment options. Finally, relevant ongoing trials focusing on systemic treatments (including [neo]adjuvant treatments and chemotherapy) enrolling at least 50 patients were retrieved and listed, to highlight ongoing research and treatment optimization. Expert opinion: Disease progression in HRPCa patients is driven by local tumor extension and subclinical metastases. Therefore, the main treatment concept is a multimodal approach targeting the primary tumor with extended surgery or RT with long-term ADT and simultaneously targeting the micro-metastatic deposits. However, there is still room for further optimization. Upcoming clinical trials comparing surgery versus RT as local treatment option, numerous trials with (neo)adjuvant chemotherapy or androgen receptor signaling inhibitors will likely change the current treatment landscape. However, a multimodal treatment strategy will stay as the cornerstone in the treatment of HRPCa. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | http://lsmu.lvb.lt/LSMU:ELABAPDB75623527&prefLang=en_USTest |
| الإتاحة: | https://doi.org/10.1080/14737140.2021.1852932Test http://lsmu.lvb.lt/LSMU:ELABAPDB75623527&prefLang=en_USTest |
| رقم الانضمام: | edsbas.36417645 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |